Vertex' Dueling Phase III Programs Pay Off In NDA Submission Speed

 
• By Bridget Silverman
  
Generate a summary of this article
Listen to this article
Beta

Next-generation CFTR corrector elexacaftor aims to be first cystic fibrosis product with minimal function mutations claim after winning out over VX-659 thanks to tolerability advantage in dueling Phase III programs testing combination with the components of Vertex’ Symdeko.

Vertex Pharmaceuticals Inc.’s latest new drug application in cystic fibrosis could introduce therapy for the underlying cause of the disease to patients with mutations that result in minimal cystic fibrosis transmembrane conductance regulator (CFTR) gene function – “the largest remaining group of people with CF that still do not have an approved Vertex medicine,” the company noted.

Vertex announced the NDA submission for the novel next-generation CFTR corrector elexacaftor (VX-445) in combination with the CFTR corrector tezacaftor...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D

  • India Tightens Oversight Of CROs With Mandatory Registration

     
    • By Vibha Sharma

    Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

  • Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

     
    • By Sue Sutter

    The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

  • How To Decarbonize Pharma R&D

     
    • By Francesca Bruce

    As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.